The European Agency for the Evaluation of Medicinal Products
Evaluation of Medicines for Human Use

London, 12 December 2000
Doc. Ref: EMEA/H/38570/00

WITHDRAWAL OF THE MARKETING AUTHORISATION FOR THE MEDICINAL PRODUCT "ECOKINASE - Reteplase" EU/1/96/017/001

- On 29 August 1996, the European Commission issued a Marketing Authorisation valid throughout the European Union for the medicinal product Ecokinase, which contains reteplase. The pharmaceutical company responsible for this medicinal product was Galenus Mannheim.
- On 28 January 1999, the Marketing Authorisation holder notified the European Commission about the Marketing Authorisation holder's decision to withdraw the Marketing Authorisation for Ecokinase.
- On 30 July 1999, the European Commission adopted the decision withdrawing the Marketing Authorisation for the medicinal product for human use "ECOKINASE – Reteplase" EU/1/96/017/001. Pursuant to this decision the European Public Assessment Report for Reteplase has been removed from the EMEA website.
- For information, it should be noted that at present there is still a Marketing Authorisation valid throughout the European Union for the medicinal product Rapilysin, which contains reteplase. The pharmaceutical company responsible for this medicinal product is Roche Registration Ltd., UK.

Mr. N. Wathion
Head of Unit Evaluation of Medicines for Human Use
Tel.: (+44-20-7) 418 8592
Fax: (+44-20-7) 418 8613

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Switchboard (44-20-7) 418 8400 Fax (44-20-7) 418 8613
E-mail: mail@emea.eudra.org http://www.eudra.org/emea.html